Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
2.72 (1y: -77%)
Market Cap 140.7 M P/E(ttm)
Enterprise Value P/B 1.30
AVEO- NAS (USA)
AVEO Pharmaceuticals, Inc.
Not Rated
Top Ranked Predictable Companies
$2.72
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
Cash to Debt 6.168
AVEO's Cash to Debt is ranked lower than
60% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AVEO: 6.168 )
AVEO' s 10-Year Cash to Debt Range
Min: 1.54   Max: 9.15
Current: 6.17
1.54
9.15
Equity to Asset 0.573
AVEO's Equity to Asset is ranked higher than
61% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.54 vs. AVEO: 0.573 )
AVEO' s 10-Year Equity to Asset Range
Min: -3.21   Max: 0.76
Current: 0.57
-3.21
0.76
F-Score: 2
Z-Score: -1.03
M-Score: -2.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
Operating margin (%) -578.80
AVEO's Operating margin (%) is ranked lower than
81% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -52.55 vs. AVEO: -578.80 )
AVEO' s 10-Year Operating margin (%) Range
Min: -578.8   Max: 20.6
Current: -578.8
-578.8
20.6
Net-margin (%) -593.1
AVEO's Net-margin (%) is ranked lower than
82% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -55.70 vs. AVEO: -593.1 )
AVEO' s 10-Year Net-margin (%) Range
Min: -593.1   Max: 18.6
Current: -593.1
-593.1
18.6
ROE (%) -96.2
AVEO's ROE (%) is ranked lower than
63% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -16.60 vs. AVEO: -96.2 )
AVEO' s 10-Year ROE (%) Range
Min: -96.2   Max: 13.7
Current: -96.2
-96.2
13.7
ROA (%) -55.1
AVEO's ROA (%) is ranked lower than
67% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -14.40 vs. AVEO: -55.1 )
AVEO' s 10-Year ROA (%) Range
Min: -81   Max: 10.4
Current: -55.1
-81
10.4
ROC (Joel Greenblatt) (%) -1050.70
AVEO's ROC (Joel Greenblatt) (%) is ranked lower than
64% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -0.20 vs. AVEO: -1050.70 )
AVEO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1050.7   Max: -1050.7
Current: -1050.7
Revenue Growth (%) -19.5
AVEO's Revenue Growth (%) is ranked lower than
58% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. AVEO: -19.5 )
AVEO' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -19.5
Current: -19.5
EBITDA Growth (%) 5.7
AVEO's EBITDA Growth (%) is ranked lower than
68% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -11.35 vs. AVEO: 5.7 )
AVEO' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 5.7
Current: 5.7
0
5.7
EPS Growth (%) 4.3
AVEO's EPS Growth (%) is ranked lower than
56% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. AVEO: 4.3 )
AVEO' s 10-Year EPS Growth (%) Range
Min: 0   Max: 4.3
Current: 4.3
0
4.3
» AVEO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

AVEO Guru Trades in Q2 2012

Steven Cohen 377,123 sh (+113.55%)
Seth Klarman 5,084,652 sh (unchged)
Jim Simons Sold Out
Jeremy Grantham Sold Out
Paul Tudor Jones 18,400 sh (-57.99%)
» More
Q3 2012

AVEO Guru Trades in Q3 2012

Jeremy Grantham 19,800 sh (New)
Seth Klarman 5,084,652 sh (unchged)
Paul Tudor Jones 13,300 sh (-27.72%)
Steven Cohen 50,000 sh (-86.74%)
» More
Q4 2012

AVEO Guru Trades in Q4 2012

Jim Simons 209,300 sh (New)
Paul Tudor Jones 65,700 sh (+393.98%)
Steven Cohen Sold Out
Seth Klarman 4,902,850 sh (-3.58%)
» More
Q1 2013

AVEO Guru Trades in Q1 2013

Jim Simons 305,118 sh (+45.78%)
Seth Klarman 4,902,850 sh (unchged)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AVEO

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2011-12-31 Sold Out 0.0031%$14.53 - $17.35 $ 2.9-66%0
Seth Klarman 2011-09-30 Add 12.79%0.29%$15.12 - $20.77 $ 2.9-84%5000000
George Soros 2011-09-30 Reduce -92.8%0.04%$15.12 - $20.77 $ 2.9-84%11600
Seth Klarman 2011-06-30 Add 25.76%0.78%$13.06 - $20.66 $ 2.9-83%4433010
George Soros 2011-06-30 New Buy0.05%$13.06 - $20.66 $ 2.9-83%161000
Seth Klarman 2011-03-31 Add 76.25%1.15%$13.15 - $15.02 $ 2.9-80%3525000
Seth Klarman 2010-12-31 New Buy1.68%$13.84 - $17.41 $ 2.9-81%2000000
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about AVEO Pharmaceuticals, Inc.

Weekly CEO Buys Highlight: AVEO, ZAZA, TUES, TUES, FRAN, AKVA
December 16, 2012
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...

Ratios

vs
industry		 vs
history
P/B 1.30
AVEO's P/B is ranked higher than
69% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. AVEO: 1.30 )
AVEO' s 10-Year P/B Range
Min: 0.88   Max: 22.16
Current: 1.3
0.88
22.16
P/S 6.94
AVEO's P/S is ranked lower than
83% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 6.90 vs. AVEO: 6.94 )
AVEO' s 10-Year P/S Range
Min: 2.83   Max: 111.5
Current: 6.94
2.83
111.5
EV-to-EBIT 0.2
AVEO's EV-to-EBIT is ranked higher than
68% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 14.61 vs. AVEO: 0.2 )
AVEO' s 10-Year EV-to-EBIT Range
Min: 6.3   Max: 16.9
Current: 0.2
6.3
16.9

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 2.1
AVEO's Price/Net Cash is ranked higher than
74% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.80 vs. AVEO: 2.1 )
AVEO' s 10-Year Price/Net Cash Range
Min: 4.8   Max: 6.1
Current: 2.1
4.8
6.1
Price/Net Current Asset Value 8.8
AVEO's Price/Net Current Asset Value is ranked higher than
79% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 32.60 vs. AVEO: 8.8 )
AVEO' s 10-Year Price/Net Current Asset Value Range
Min: 20.1   Max: 146.2
Current: 8.8
20.1
146.2
Price/Tangible Book 1.3
AVEO's Price/Tangible Book is ranked higher than
62% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. AVEO: 1.3 )
AVEO' s 10-Year Price/Tangible Book Range
Min: 2.9   Max: 5.2
Current: 1.3
2.9
5.2
Price/Median PS Value 1.3
AVEO's Price/Median PS Value is ranked higher than
99% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. AVEO: 1.3 )
AVEO' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 3.5
Current: 1.3
0.7
3.5
Earnings Yield (Greenblatt) 576.40
AVEO's Earnings Yield (Greenblatt) is ranked higher than
77% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. AVEO: 576.40 )
AVEO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.9   Max: 584.6
Current: 576.4
5.9
584.6

Business Description

AVEO Pharmaceuticals Inc. was incorporated under the laws of the State of Delaware on October 19, 2001 as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. on March 1, 2005. The company is a cancer therapeutics company committed to discovering, developing and commercializing targeted cancer therapies to impact patients' lives. The company is seeking to develop multiple new drugs that target important mechanisms known or believed to be involved in cancer. The company's product pipeline includes its drug candidate, tivozanib, a small molecule oral cancer drug designed to prevent tumor growth by inhibiting angiogenesis, as well as monoclonal antibodies against HGF and ErbB3. It's also developing a pipeline of earlier stage, novel antibodies that are designed to target mechanisms. Tivozanib was partnered with Astellas Pharma Inc. It also demonstrated a statistically significant improvement in PFS with a median PFS of 12.7 months compared to a median PFS of 9.1 months for Nexavar in the pre-specified subpopulation of patients who received no prior systemic anti-cancer therapy for metastatic disease—a subpopulation that comprised approximately 70% of the total study population. In addition to the TIVO-1 study, the company is evaluating tivozanib in multiple phases 1 and phases 2 clinical trials including its BATON (Biomarker Assessment of Tivozanib in ONcology) program, a series of clinical trials assessing tivozanib biomarkers in solid tumors. The company has acquired exclusive rights to develop and commercialize tivozanib worldwide outside of Asia pursuant to a license agreement it entered into with Kirin Brewery Co. Ltd in 2006. Under the license agreement, it obtained an exclusive license to research, develop, manufacture and commercialize tivozanib, pharmaceutical compositions thereof and associated biomarkers for the diagnosis, prevention and treatment of any and all human diseases and conditions outside of Asia. KHK has retained all rights to tivozanib in Asia. The company's proprietary Human Response Platform was designed to overcome many of the limitations of traditional approaches to modeling human cancer. Its main competitors includes pharmaceutical companies, biotechnology companies and academic institutions which are competing with the company in the field of oncology and filing patent applications potentially relevant to the company business. The Company's activities are subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services, the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, and state and local governments.
Company Website
SEC Reports
Industry: Biotechnology
Compare:
Traded in other countries:VPA.Germany
» More Articles for AVEO

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: AVEO, ZAZA, TUES, TUES, FRAN, AKVA Dec 16 2012 
Seth Klarman’s Baupost Group Buys HPQ, BP, NWS, GNW, NG Nov 14 2011 
Seth Klarman’s Baupost Group Buys Microsoft Corp., BP, Allied Nevada Gold, Sells Audiovox Corp. Aug 12 2011 
Seth Klarman’s Baupost Group Q1 Portfolio Update; Buys ANV, SCMR, PDLI, AVEO May 14 2011 
AVEO Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
Interview with Prof. Bruce Greenwald; Insight in Value Investing Feb 28 2011 
Two Picks from Seth Klarman: PDLI, AVEO Feb 22 2011 
Hedge Fund Baupost Group buys PDLI, AVEO, ALR, Sells LSTZA, UFS, SLRC, EXXI Feb 11 2011 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial